Intrinsiqq
Viskase Holdings, Inc. logo

Viskase Holdings, Inc. Financials

ENZN

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 18 available years
Income Statement
TTM
~393.2:1 split
DEC 2025
DEC 2024
DEC 2023
1000:1 split
DEC 2022
DEC 2021
Revenues
Revenue$363–$0–$0$1
Cost of Revenue$329–––––
Gross Profit$34–––––
Operating Expenses
Selling & Marketing$10–––––
General & Administrative$49–––––
Research & Development$3–––––
Provision for Doubtful Accounts–$0$0––$0
Total Operating Expenses$62$5$1$1$1$1
Operating Income-$19-$5-$1-$1-$1-$0
Other Non-Operating Income (Expense)$2–––––
EBT (Earnings Before Tax)-$28-$3$1$1-$0-$0
Income Tax Expense$3$0$0-$0-$0$0
Minority Interest-$0–––––
Net Income
Net Income-$31-$3$1$1-$0-$0
Per Share Data
Revenue Per Share$25.34–$0.71–$713.25$19,230.28
EPS (Basic)-$4.04-$142.51-$20.36$0.00-$40.72-$61.08
EPS (Diluted)-$4.04-$142.51-$20.36$0.00-$40.72-$61.08
Weighted Avg Shares (Basic)14.3M74.2M74.2M74.2M74,21574,215
Weighted Avg Shares (Diluted)14.3M74.2M74.2M74.2M74,21574,215
Shares Outstanding14.3M36,452.92436,452.92436,452.92436.45336.453
Dividends Per Share$0.00$34.98$34.98$34.98–$0.00

Viskase Holdings (ENZN) financials: revenue, profit and margins

Viskase Holdings (ENZN) generated about n/a in revenue and -$7 million in net income over the trailing twelve months, growing at roughly -67.3% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Viskase Holdings profitable?+

Viskase Holdings reported about -$7 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Viskase Holdings growing?+

Viskase Holdings's revenue has compounded at roughly -67.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside ENZN's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 1 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 4 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ENZN

CompareIntrinsic value
SNTISenti Biosciences Inc.
$0.18-0.79%0
CELZCreative Medical Technology Holdings Inc.
$0.65-3.21%10
INMBInmune Bio Inc.
$1.33+0.76%10
AIMAIM ImmunoTech Inc.
$0.16+0.63%15
VIVSVivoSim Labs, Inc.
$0.15+8.71%10
ATYRAtyr Pharma Inc.
$6.18-6.79%10
WINTWindtree Therapeutics Inc.
$0.00+0.00%10
ZIVOZivo Bioscience Inc.
$8.00+10.34%0

Spot a number that looks wrong? Check it in ENZN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ENZN

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.